FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2296910921> ?p ?o ?g. }

• W2296910921 endingPage "1120" @default.
• W2296910921 startingPage "1120" @default.
• W2296910921 abstract "Evidence from preclinical models indicates that xenon gas can prevent the development of cerebral damage after acute global hypoxic-ischemic brain injury but, thus far, these putative neuroprotective properties have not been reported in human studies.To determine the effect of inhaled xenon on ischemic white matter damage assessed with magnetic resonance imaging (MRI).A randomized single-blind phase 2 clinical drug trial conducted between August 2009 and March 2015 at 2 multipurpose intensive care units in Finland. One hundred ten comatose patients (aged 24-76 years) who had experienced out-of-hospital cardiac arrest were randomized.Patients were randomly assigned to receive either inhaled xenon combined with hypothermia (33°C) for 24 hours (n = 55 in the xenon group) or hypothermia treatment alone (n = 55 in the control group).The primary end point was cerebral white matter damage as evaluated by fractional anisotropy from diffusion tensor MRI scheduled to be performed between 36 and 52 hours after cardiac arrest. Secondary end points included neurological outcome assessed using the modified Rankin Scale (score 0 [no symptoms] through 6 [death]) and mortality at 6 months.Among the 110 randomized patients (mean age, 61.5 years; 80 men [72.7%]), all completed the study. There were MRI data from 97 patients (88.2%) a median of 53 hours (interquartile range [IQR], 47-64 hours) after cardiac arrest. The mean global fractional anisotropy values were 0.433 (SD, 0.028) in the xenon group and 0.419 (SD, 0.033) in the control group. The age-, sex-, and site-adjusted mean global fractional anisotropy value was 3.8% higher (95% CI, 1.1%-6.4%) in the xenon group (adjusted mean difference, 0.016 [95% CI, 0.005-0.027], P = .006). At 6 months, 75 patients (68.2%) were alive. Secondary end points at 6 months did not reveal statistically significant differences between the groups. In ordinal analysis of the modified Rankin Scale, the median (IQR) value was 1 (1-6) in the xenon group and 1 (0-6) in the control group (median difference, 0 [95% CI, 0-0]; P = .68). The 6-month mortality rate was 27.3% (15/55) in the xenon group and 34.5% (19/55) in the control group (adjusted hazard ratio, 0.49 [95% CI, 0.23-1.01]; P = .053).Among comatose survivors of out-of-hospital cardiac arrest, inhaled xenon combined with hypothermia compared with hypothermia alone resulted in less white matter damage as measured by fractional anisotropy of diffusion tensor MRI. However, there was no statistically significant difference in neurological outcomes or mortality at 6 months. These preliminary findings require further evaluation in an adequately powered clinical trial designed to assess clinical outcomes associated with inhaled xenon among survivors of out-of-hospital cardiac arrest.clinicaltrials.gov Identifier: NCT00879892." @default.
• W2296910921 created "2016-06-24" @default.
• W2296910921 creator A5000486333 @default.
• W2296910921 creator A5004220016 @default.
• W2296910921 creator A5004697375 @default.
• W2296910921 creator A5006418280 @default.
• W2296910921 creator A5012324528 @default.
• W2296910921 creator A5014280780 @default.
• W2296910921 creator A5016538193 @default.
• W2296910921 creator A5019913656 @default.
• W2296910921 creator A5022802779 @default.
• W2296910921 creator A5023722090 @default.
• W2296910921 creator A5025518615 @default.
• W2296910921 creator A5026529813 @default.
• W2296910921 creator A5031521183 @default.
• W2296910921 creator A5032505487 @default.
• W2296910921 creator A5034563349 @default.
• W2296910921 creator A5037429588 @default.
• W2296910921 creator A5037736487 @default.
• W2296910921 creator A5041635447 @default.
• W2296910921 creator A5049593876 @default.
• W2296910921 creator A5051401280 @default.
• W2296910921 creator A5055664323 @default.
• W2296910921 creator A5064800394 @default.
• W2296910921 creator A5064820811 @default.
• W2296910921 creator A5065301160 @default.
• W2296910921 creator A5066668398 @default.
• W2296910921 creator A5069490876 @default.
• W2296910921 creator A5070281465 @default.
• W2296910921 creator A5072161347 @default.
• W2296910921 creator A5087566716 @default.
• W2296910921 creator A5090824196 @default.
• W2296910921 date "2016-03-15" @default.
• W2296910921 modified "2023-10-13" @default.
• W2296910921 title "Effect of Inhaled Xenon on Cerebral White Matter Damage in Comatose Survivors of Out-of-Hospital Cardiac Arrest" @default.
• W2296910921 cites W1633272553 @default.
• W2296910921 cites W1676366316 @default.
• W2296910921 cites W1977446339 @default.
• W2296910921 cites W1983444048 @default.
• W2296910921 cites W1989666863 @default.
• W2296910921 cites W1994972002 @default.
• W2296910921 cites W2003880271 @default.
• W2296910921 cites W2006096283 @default.
• W2296910921 cites W2016984624 @default.
• W2296910921 cites W2022755804 @default.
• W2296910921 cites W2023169605 @default.
• W2296910921 cites W2025047388 @default.
• W2296910921 cites W2029569324 @default.
• W2296910921 cites W2032019180 @default.
• W2296910921 cites W2040811723 @default.
• W2296910921 cites W2046557060 @default.
• W2296910921 cites W2047152236 @default.
• W2296910921 cites W2055298140 @default.
• W2296910921 cites W2060211312 @default.
• W2296910921 cites W2060416311 @default.
• W2296910921 cites W2070949043 @default.
• W2296910921 cites W2071497357 @default.
• W2296910921 cites W2104869294 @default.
• W2296910921 cites W2109887441 @default.
• W2296910921 cites W2112321151 @default.
• W2296910921 cites W2114091391 @default.
• W2296910921 cites W2115345807 @default.
• W2296910921 cites W2116319090 @default.
• W2296910921 cites W2118359102 @default.
• W2296910921 cites W2120683729 @default.
• W2296910921 cites W2126370082 @default.
• W2296910921 cites W2139621750 @default.
• W2296910921 cites W2148828979 @default.
• W2296910921 cites W2150667092 @default.
• W2296910921 cites W2164875057 @default.
• W2296910921 cites W2166662384 @default.
• W2296910921 cites W2171886225 @default.
• W2296910921 cites W2334744999 @default.
• W2296910921 cites W2460901287 @default.
• W2296910921 cites W2497721881 @default.
• W2296910921 cites W81660439 @default.
• W2296910921 cites W2106763716 @default.
• W2296910921 doi "https://doi.org/10.1001/jama.2016.1933" @default.
• W2296910921 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26978207" @default.
• W2296910921 hasPublicationYear "2016" @default.
• W2296910921 type Work @default.
• W2296910921 sameAs 2296910921 @default.
• W2296910921 citedByCount "96" @default.
• W2296910921 countsByYear W22969109212015 @default.
• W2296910921 countsByYear W22969109212016 @default.
• W2296910921 countsByYear W22969109212017 @default.
• W2296910921 countsByYear W22969109212018 @default.
• W2296910921 countsByYear W22969109212019 @default.
• W2296910921 countsByYear W22969109212020 @default.
• W2296910921 countsByYear W22969109212021 @default.
• W2296910921 countsByYear W22969109212022 @default.
• W2296910921 countsByYear W22969109212023 @default.
• W2296910921 crossrefType "journal-article" @default.
• W2296910921 hasAuthorship W2296910921A5000486333 @default.
• W2296910921 hasAuthorship W2296910921A5004220016 @default.
• W2296910921 hasAuthorship W2296910921A5004697375 @default.
• W2296910921 hasAuthorship W2296910921A5006418280 @default.
• W2296910921 hasAuthorship W2296910921A5012324528 @default.

• next